Proprietary and patented innovations in m-health


Brighter is a Swedish medical technology company founded in 2007. Brighter’s goal is to simplify, streamline and strengthen relationships between patients and healthcare services by developing innovations within m-health (mobile healthcare). In a first step, the company has developed an integrated solution (Actiste) to facilitate the management and control of insulin therapy in diabetics.

Initial product launch - Actiste

The company’s initial product, Actiste, is a complete mobile health device for diabetics. It includes an insulin pen, a blood glucose meter and a logbook. The logbook is cloud-based, which means that, if the user so wishes, it can report and transfer patient data via 3G connectivity to selected recipients, including relatives, healthcare services and researchers. An m-health device allows healthcare providers to pass on some elements of the diagnostics, logging in and treatment of the patient, providing valuable data to patients, healthcare providers and researchers while at the same time it can lead to cost savings in healthcare. For this, Brighter has a cloud-based service called The Benefit Loop.

The company plans to launch Actiste in 2018 and has entered into several collaborations in order to ensure delivery and quality. Through cooperation with Ericsson, an agreement has been reached with Indosat Ooredoo (Indonesia) and AIS (Thailand). For Sweden, the company has previously signed an agreement with Telia through which Actiste will be offered on Telia’s digital Healthcare solution.

In addition to collaborations for the connection of Actiste, Sonat has been chosen as a development partner for a global logistics solution. There will be an outsourced logistics function with responsibility for elements such as forecasts, inventory control, availability, order planning, transport management, delivery monitoring and ongoing problem solving. For the production itself, Sanmina is the production partner for the first generation of Actiste.

Initial focus markets

Brighter’s first focus markets for Actiste are Northern Europe (Sweden initially) and Southeast Asia (Indonesia and Thailand initially). The revenue model is divided into two parts: consumers and insurance systems. The data uploaded to The Benefit Loop cloud service may in the future become a further revenue stream if it proves valuable to government agencies, for example. The company plans to sell Actiste via a subscription model that will initially target the consumer market. In addition to Actiste, the company plans for the subscription to also include test sticks, needles, connection, data storage and a mobile app.

Sweden will act as a reference market for the rest of the world. The launch will initially take place in Sweden, Thailand and Indonesia.

The global diabetes market is huge. Brighter estimates that approximately 37% of the total 415 million diabetes patients should use insulin on a daily basis. In broad terms, this means 150 million potential users. If we break down this figure for Sweden alone, it comes to around 150,000 with annual growth of 1.5%. New solutions within e-health are welcomed to meet ever-increasing costs in healthcare, partly because of an aging population. Brighter’s IP platform may in future also be used in areas other than diabetes where injection is required.

The Benefit Loop

As we mentioned above, the data delivered from a product such as Actiste will end up in Brighter’s cloud service, The Benefit Loop. Here, patients should be able to log in to follow their treatment and ensure its quality. The data is stored centrally and can be shared with the patient’s doctor, who can easily monitor the patient’s well-being. However, the patient may also choose to share data with relatives or, for example, researchers. The Loop can be broken down into four steps:

  1. Treat - The patient treats their illness, for example by using insulin as instructed by a doctor.
  2. Log - The information is logged and stored automatically and made available to share.
  3. Analyze - The data is visualised in an educational and smart way and made readily available for analysis.
  4. Improve - Feedback to the patient to improve the treatment.

More effective care

The cost of care is high and is expected to continue to increase as a share of GDP. For 2013, the WHO estimates that public health expenses amounted to 6.9% of Swedish GDP, and this is expected to rise to 7.3% by 2050. If we also include private fees, this percentage is even higher. An aging population is putting pressure on an already-stretched healthcare system, which means that new technical solutions are being sought to make it more effective.

Global investments in digital health are expected to grow by an average of 21% per year in 2015-2020. The fastest growing segment is mobile healthcare solutions, expanding by 41% in 2015-2020.

Camanio Care

In 2015, Brighter acquired the company behind the technology in the jDome product. The technology is based on connecting a computer to a projector that places images or videos on a large screen surrounding the viewer. In October 2016, Brighter announced that it was to merge the jDome business with Bestic. Brighter AB therefore acquired Bestic AB through its subsidiary Brighter Two AB. The combined company was listed on 28 March 2017 under the name of Camanio Care AB. As of 31 December 2017, Brighter owned 26.51% of Camanio Care.

Tell a friend

Here you can tip someone by sending a link to this page:


Share this link to your network through social media.